Ironwood Pharmaceuticals Stock Income Statements

Ironwood Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Ironwood Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31

revenues:
collaborative arrangements revenue	85,239,000	41,143,000	90,545,000	91,592,000	94,396,000	74,877,000	117,553,000	113,739,000	107,382,000	104,061,000	107,199,000	108,637,000	97,231,000	97,529,000	116,986,000	103,747,000	103,386,000	88,665,000	114,209,000	103,468,000	89,423,000	74,445,000	105,654,000	130,524,000	77,322,000	66,152,000	84,352,000	54,194,000	71,207,000	63,086,000	62,901,000	86,143,000	64,612,000	51,877,000	87,459,000	66,106,000	54,350,000	66,042,000	39,572,000	27,744,000	28,932,000	16,918,000	6,840,000	14,605,000	9,663,000	3,255,000	96,413,000	14,604,000	12,248,000	12,218,000	11,262,000	10,237,000	9,059,000
total revenues	85,239,000	41,143,000	90,545,000	91,592,000	94,396,000	74,877,000	117,553,000	113,739,000	107,382,000	104,061,000	107,199,000	108,637,000	97,231,000	97,529,000	117,130,000	103,747,000	104,031,000	88,845,000	116,680,000	103,468,000	89,432,000	79,943,000	126,301,000	131,167,000	102,215,000	68,730,000	130,692,000	65,686,000	81,106,000	69,155,000	94,208,000	86,825,000	65,077,000	52,166,000
costs and expenses:
research and development	23,373,000	27,432,000	25,391,000	29,827,000	30,388,000	25,815,000	35,676,000	32,985,000	34,577,000	12,847,000	10,446,000	11,545,000	11,452,000	10,822,000	31,851,000	10,907,000	12,163,000	15,484,000	16,267,000	21,692,000	22,076,000	28,027,000	26,537,000	27,551,000	28,758,000	53,990,000	44,272,000	46,794,000	38,932,000	36,505,000	40,117,000	37,065,000	37,344,000	33,702,000	38,442,000	37,526,000	31,682,000	31,842,000	25,830,000	28,648,000	26,641,000	25,122,000	22,142,000	27,144,000	24,093,000	32,753,000	23,453,000	32,238,000	29,510,000	22,905,000	19,409,000	19,555,000	18,742,000	20,953,000	18,637,000
selling, general and administrative	16,795,000	24,260,000	33,590,000	36,113,000	36,964,000	37,605,000	38,667,000	36,046,000	52,484,000	31,117,000	28,390,000	28,619,000	30,124,000	28,861,000	28,687,000	27,742,000	27,052,000	27,652,000	33,982,000	34,928,000	34,643,000	36,450,000	39,190,000	40,919,000	43,246,000	64,741,000	58,179,000	55,248,000	68,363,000	61,923,000	57,953,000	61,774,000	57,792,000	55,604,000	55,208,000	44,987,000	36,918,000	36,168,000	30,439,000	32,955,000	30,346,000	28,535,000	29,299,000	29,924,000	30,870,000	33,374,000
restructuring	-250,000	18,559,000	73,000	16,000	2,067,000
total costs and expenses	39,918,000	70,251,000	59,054,000	65,956,000	69,419,000	63,857,000	79,964,000	73,716,000	1,190,521,000
income from operations	45,321,000	-29,108,000	31,491,000	25,636,000	24,977,000	11,020,000	37,589,000	40,023,000	-1,083,139,000	60,097,000	68,363,000	68,473,000	55,655,000	57,846,000	56,592,000	65,171,000	65,098,000	45,398,000	51,384,000	45,616,000	32,713,000	13,227,000	49,593,000	65,887,000	21,577,000	-54,372,000	5,995,000	-169,099,000	-39,920,000	-35,868,000	22,765,000	-19,434,000	-41,011,000	-39,705,000	-6,300,000	-28,287,000											47,608,000
yoy	81.45%	-364.14%	-16.22%	-35.95%	-102.31%	-81.66%	-45.02%	-41.55%	-2046.17%	3.89%	20.80%	5.07%	-14.51%	27.42%	10.14%	42.87%	99.00%	243.22%	3.61%	-30.77%	51.61%	-124.33%	727.24%	-138.96%	-154.05%	51.59%	-73.67%	770.12%	-2.66%	-9.66%	-461.35%	-31.30%
qoq	-255.70%	-192.43%	22.84%	2.64%	126.65%	-70.68%	-6.08%	-103.70%	-1902.32%	-12.09%	-0.16%	23.03%	-3.79%	2.22%	-13.16%	0.11%	43.39%	-11.65%	12.64%	39.44%	147.32%	-73.33%	-24.73%	205.36%	-139.68%	-1006.96%	-103.55%	323.59%	11.30%	-257.56%	-217.14%	-52.61%	3.29%	530.24%	-77.73%
operating margin %
other income:
interest expense and other financing costs	-8,356,000	-8,070,000	-8,914,000	-9,419,000	-7,470,000	-7,231,000	-8,423,000	-9,839,000	-1,840,000
interest and investment income	818,000	869,000	778,000	1,152,000	1,369,000	1,169,000	1,194,000	1,748,000	8,757,000	7,272,000	5,446,000	2,807,000	1,018,000	230,000	180,000	178,000	172,000	196,000	220,000	231,000	276,000	777,000	565,000	893,000	668,000	736,000	837,000	741,000	732,000	681,000	619,000	601,000	496,000	395,000	346,000	307,000	295,000	221,000	156,000	71,000	65,000	71,000	65,000	44,000	49,000	52,000	41,000	44,000	49,000	105,000	125,000	154,000	188,000	189,000	68,000
other	39,000	37,000
other income	-7,499,000	-7,164,000	-7,496,000	-8,267,000	-6,101,000	-6,062,000	-7,229,000	-8,091,000	6,917,000	5,764,000	-454,250	1,434,000	-1,870,000	-1,381,000					-3,000			27,000	306,000	68,000	140,000	-4,912,000	-21,488,000	-5,252,000	-9,460,000	-7,276,000	-7,218,000	-12,863,000	-3,213,000	-12,796,000	-5,658,250	-4,917,000														897,000		3,000	107,000	110,000
income before income taxes	37,822,000	-36,272,000	23,995,000	17,369,000	18,876,000	4,958,000	30,360,000	31,932,000	-1,076,222,000	65,861,000	72,265,000	69,907,000	53,785,000	56,465,000	38,600,500	59,672,000	54,372,000	40,358,000
income tax expense	-14,223,000	-1,114,000	-21,739,000	-13,723,000	-19,736,000	-9,120,000	-12,846,250	-17,982,000	-13,256,000	-20,147,000				-17,664,000				-432,000	1,296,000	1,389,000
net income	23,599,000	-37,386,000	2,256,000	3,646,000	-860,000	-4,162,000	-1,745,000	13,950,000															47,858,000	20,648,000	12,283,000	-59,284,000	-15,493,000	-174,351,000	-49,380,000	-43,144,000	12,085,000	-32,297,000	-44,224,000	-52,501,000	-13,505,000	-33,204,000	-21,702,000	-13,297,000	-47,390,000	-48,020,000	-33,222,000	-41,988,000	-60,357,000	-49,626,000	-65,149,000	-93,902,000	47,635,000	-40,803,000
yoy	-2844.07%	798.27%	-229.28%	-73.86%																			-408.90%	-111.84%	-124.87%	37.41%	-228.20%	439.84%	11.66%	-17.82%	-189.49%	-2.73%	103.78%	294.83%	-71.50%	-30.85%	-34.68%	-68.33%	-21.48%	-3.24%	-49.01%	-55.29%	-226.71%	21.62%
qoq	-163.12%	-1757.18%	-38.12%	-523.95%	-79.34%	138.51%	-112.51%																131.78%	68.10%	-120.72%	282.65%	-91.11%	253.08%	14.45%	-457.00%	-137.42%	-26.97%	-15.77%	288.75%	-59.33%	53.00%	63.21%	-71.94%	-1.31%	44.54%	-20.88%	-30.43%	21.62%	-23.83%	-30.62%	-297.13%	-216.74%
net income margin %

net income per share	0.15	-0.23	0.02	0.02	-0.01	-0.03		0.1	-6.84	0.3	0.31	0.33	0.24	0.25	0.25	0.34	2.42	0.25	0.27	0.22	0.16	0.02	0.31	0.13	0.08	-0.38	-0.1	-1.14	-0.32	-0.29	0.09	-0.22	-0.3	-0.36	-0.09	-0.23	-0.15	-0.09	-0.33	-0.34	-0.24	-0.3	-0.44	-0.38	-0.57	-0.87		-0.38	-0.34	-0.21	-0.19	-0.19	-0.08	-0.18	-0.25
weighted-average shares used for eps calculation	161,723	160,974	159,083	159,706	159,014	157,700	155,435	155,886	155,367	154,452	154,366	153,066	153,304	157,821	162,245	162,742	161,948	160,967	159,427	159,846	159,407	158,374
acquired in-process research and development							5,000,000		1,090,449,000
gain on derivatives										19,000	-18,000	151,000	-681,000	730,000	-2,566,000	2,164,000		2,390,000			-467,000	-3,466,000	4,517,000	-4,766,000	-672,000	3,944,000	-12,739,000	3,489,000	-809,000	1,316,000	-2,093,000	-4,329,000	5,337,000		2,103,000	4,541,000	3,145,000
less: net income attributable to noncontrolling interests							-658,000	-1,371,000
net income attributable to ironwood pharmaceuticals, inc.			2,256,000	3,646,000	-860,000		-1,087,000	15,321,000																																										-20,633,000	-18,844,000	-18,401,000	-8,270,000	-17,136,000	-15,924,000
restructuring expenses						437,000	621,000	4,685,000	13,011,000							-73,000	-282,000	311,000	14,150,000	1,232,000			-32,000	-166,000	490,000	3,328,000	783,000	10,282,000	2,392,000
net income and comprehensive income									-1,089,478,000	45,714,000	48,867,000	50,317,000	37,080,000	38,801,000	41,374,000	55,845,000	391,303,000	39,926,000	15,743,000	34,423,000	25,204,000	3,345,000
less: net income and comprehensive income attributable to noncontrolling interests									-27,291,000
net income and comprehensive income attributable to ironwood pharmaceuticals, inc.									-1,062,187,000
operating expenses:
total operating expenses										43,964,000	38,836,000	40,164,000	41,576,000	39,683,000																																	48,805,000	55,438,000	47,884,000	33,834,000	30,214,000	28,779,000	25,224,000	28,278,000	25,280,000
interest expense										-1,527,000	-1,526,000	-1,524,000	-2,207,000	-2,341,000	-7,951,000	-7,841,000	-7,732,000	-7,626,000	-7,521,000	-7,419,000	-7,318,000	-7,220,000	-7,123,000	-10,457,000	-9,430,000	-9,592,000	-9,586,000	-9,482,000	-9,383,000	-9,273,000	-9,206,000	-9,135,000	-9,046,000	-8,983,000	-9,654,000	-9,765,000
sale of active pharmaceutical ingredient															144,000		645,000	180,000	2,471,000		9,000	5,498,000	20,647,000	643,000	24,893,000	2,578,000	45,861,000	10,257,000	8,803,000	5,434,000
income tax benefit											-23,398,000	-19,590,000	-16,705,000		-4,881,000	-3,827,000	336,931,000																																	3,000
cost and expenses:
cost of revenues																			559,750			2,239,000
total cost and expenses															60,538,000	38,576,000	38,933,000	43,447,000	65,296,000	57,852,000	56,719,000	66,716,000	76,708,000	65,280,000	80,638,000	123,102,000	124,697,000	234,785,000	121,026,000	105,023,000	71,443,000	106,259,000	106,088,000	91,871,000	93,759,000	94,393,000	69,665,000	68,010,000	65,757,000	69,753,000	56,999,000	53,657,000	61,959,000	58,992,000	69,543,000	92,088,000
loss on derivatives																	-3,166,000		-1,637,250	-2,616,000														-2,199,000
write-down of commercial supply and inventory to net realizable value and settlement on non-cancellable purchase commitments
gain on lease modification																									-3,169,000
loss on extinguishment of debt																								-30,977,000										-2,009,000
income from continuing operations, before income taxes																			44,500,000	35,812,000
income from continuing operations, net of income taxes																			15,743,000	34,423,000
income from discontinued operations, net of income taxes
income per share from continuing operations, net of income taxes—basic																			0.27	0.22
income per share from continuing operations, net of income taxes—diluted																			0.27	0.21
loss per share from discontinued operations, net of income taxes—basic and diluted
net income from continuing operations																					25,204,000	3,345,000	47,858,000	20,648,000	12,283,000
net income from discontinued operations																																																					9,311,000
product revenue																											479,000	1,235,000	1,096,000	635,000	1,625,000	682,000	465,000	289,000
cost of revenues, excluding amortization of acquired intangible assets																							11,013,000	506,000	11,313,000	1,043,000	21,463,000	4,616,000	4,065,000	2,607,000	2,528,250	6,080,000
write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments																								-3,530,000			61,750	-1,589,000
amortization of acquired intangible assets																												1,159,000	3,476,000	3,476,000	684,500	1,897,000
gain on fair value remeasurement of contingent consideration
impairment of intangible assets																												151,794,000
weighted-average number of common shares—basic and diluted:																								156,436	155,849
write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments																													1,836,000
loss on fair value remeasurement of contingent consideration																													1,962,000	512,000			6,933,000	1,614,000	1,164,000	8,667,000
weighted-average number of common shares used in net income per share—basic and diluted:																										154,956	152,634	153,227	152,163	151,013	148,993	149,502	148,778	147,786	144,928	145,180
(gain) loss on fair value remeasurement of contingent consideration																												-33,519,000			-39,229,000	-628,000
write-down of lesinurad commercial supply to net realizable value																															41,750	71,000
cost of revenues, excluding amortization of acquired intangible asset																																	3,502,000	531,000
write-down of lesinurad commercial supply to net realizable value and loss on non-cancellable purchase commitments																																	96,000
amortization of acquired intangible asset																																	421,000	420,000	-3,297,000	3,213,000	1,065,000
cost of revenue, excluding amortization of acquired intangible asset
write-down of inventory to net realizable value and loss on non-cancellable purchase commitments																																							9,488,000
weighted-average number of common shares used in net income per share — basic and diluted:																																					144,642	143,593	142,473	142,098	141,278	139,234	138,315	129,745	113,441,391	108,072,643
cost of revenue																																								8,150,000	12,000		10,518,000	1,924,000	3,418,000	1,231,000
gross profit
yoy
qoq
gross margin %																																																						0%	0%
collaboration expense																																													11,162,000	24,730,000
general and administrative																																															25,352,000	23,200,000	18,374,000	10,929,000	10,805,000	9,224,000	6,482,000	7,325,000	6,643,000
net income before income taxes																																															47,635,000
basic net income per share																																															0.44
diluted net income per share																																															0.42
weighted-average number of common shares used in:
comprehensive income																																															47,651
weighted-average number of common shares used in net income per share —basic and diluted																																																107,078,150	103,751,060
comprehensive loss																																																-40,815	-35,604,000
other comprehensive income:
unrealized gain on short-term investments
other comprehensive income
net income from continuing operations before income tax benefit
net income from discontinued operations attributable to noncontrolling interest
continuing operations																																																		-0.21	-0.19	-0.19	-0.16
discontinued operations																																																					0.08
weighted-average number of common shares used in net income per share attributable to ironwood pharmaceuticals, inc.—basic and diluted																																																		100,174,100	99,674,969	99,075,187	97,925,657	97,642,330	63,957,966
remeasurement of forward purchase contracts
net (income) income from discontinued operations attributable to noncontrolling interest
revenue:
collaborative arrangements																																																						9,188,000	8,838,000
services																																																						1,771,000	214,000
total revenue																																																						10,959,000	9,052,000
yoy
qoq																																																						21.07%
net income attributable to noncontrolling interest																																																						73,000	329,000

We provide you with 20 years income statements for Ironwood Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ironwood Pharmaceuticals stock. Explore the full financial landscape of Ironwood Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Ironwood Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.